Logo

ActivX and Kyorin to Study Metabolic Disorders

Jan 08, 2004

NEW YORK, Jan.8 (GenomeWeb News) - ActivX Biosciences and Kyorin Pharmaceutical have signed a research agreement to study compounds for metabolic disorders, Kyorin said Tuesday.

 

ActivX, based in La Jolla, Calif., will use its proteomics technology to analyze the activity and toxicity mechanisms of compounds developed by Kyorin of Tokyo to treat metabolic disorders.

 

The two companies have already been collaborating since 2002  to study new drugs for type II diabetes.

 

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.